BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9479598)

  • 1. Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
    Lissoni P; Barni S; Di Felice G; Majorca F; Fumagalli L
    Int J Biol Markers; 1997; 12(3):134-6. PubMed ID: 9479598
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
    Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
    Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6 is a survival prognostic factor in renal cell carcinoma.
    Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
    Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
    Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
    Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
    Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
    Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of IL-18 secretion by IL-2 in patients with advanced cancer.
    Lissoni P; Rovelli F; Vellani D; Malugani F; Bucovec R; Chapovalenko L; Fumagalli E; Gardani G
    Int J Biol Markers; 2001; 16(2):146-7. PubMed ID: 11471899
    [No Abstract]   [Full Text] [Related]  

  • 8. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
    Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
    Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
    Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
    J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
    Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
    Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
    Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
    Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer.
    Bonfanti A; Lissoni P; Bucovec R; Rovelli F; Brivio F; Fumagalli L
    Int J Biol Markers; 2000; 15(2):161-4. PubMed ID: 10883890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
    Lissoni P; Mandalà M; Brivio F
    Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
    Kleinknecht S; Bichler KH; Strohmaier WL
    Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
    Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
    Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Ramsey S; Aitchison M
    J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble immunological parameters and early prognosis of renal cell cancer patients.
    Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
    J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
    Vannier E; Kaser A; Atkins MB; Fantuzzi G; Dinarello CA; Mier JW; Tilg H
    Eur Cytokine Netw; 1999 Mar; 10(1):37-42. PubMed ID: 10210771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy.
    Kedar I; Mermershtain W; Ivgi H
    Int J Cancer; 2004 Jun; 110(2):260-5. PubMed ID: 15069691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.